Helperby Therapeutics is providing new solutions with synergistic combinations to treat infectious diseases. Our core business has been focused on developing treatments for highly resistant bacteria and we are now also applying our expertise to address COVID-19. Helperby Therapeutics was founded by Prof Sir Anthony Coates in 2002 as a spinout from St. Georges Hospital Medical School. Prior to establishing the company, Prof Coates had built up a significant body of research to form its foundations.
Working under his mentor, Denis Mitchison, father of the randomised controlled trial and the combination therapy that is still used against Tuberculosis today, Prof Coates learnt how combinations of antibiotics were very effective.
As the trend for bacteria becoming resistant to single agent antibiotics became apparent (such as with MRSA) Prof Coates saw the opportunity to apply his experience with combinations to a growing new field.
Helperby Therapeutics was born and is today the only company developing new combinations of active antibiotics. During Helperby’s research into how to combine different drugs, we discovered that synergy was occurring between some combinations and we developed a set of techniques to identify the most synergistic combinations.
We now have a significant proprietary IP portfolio, of which 12 baskets are ready for commercialisation. Our lead program (HY001) is already in Phase II testing, with initial results due over the course of 2020. Helperby continues to benefit to this day from St George’s laboratory and research capabilities; as well as our other existing partnerships. Our approach of using antibiotics in combinations has also been adopted by the principal international antibiotic research organisation, GARDP.